Immunotoxins are being tested for the therapy of systemic cancer and b
rain tumors. Neurotoxicity has been dose limiting for several of these
antibody conjugates given systemically. We review the animal and clin
ical data related to the neurotoxicity of immunotoxins in attempt to u
nderstand the molecular basis for the unexpected neural involvement an
d to prevent or minimize this toxicity in future clinical trials.